AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Novel Group A Streptococcal Vaccine and Therapeutics

Detailed Technology Description

Scientists at UC San Diego have developed novel genetic GAS mutants expressing GAC without the GlcNAc side chain. This invention is the use of the A-variant carbohydrate purified from the mutant as a vaccine, which will induce anti-GAC antibodies that would be protective against all serotypes of GAS. The mutant GAC may also be used as a vaccine strategy against other medically important pathogens including groups C and G Streptococcus (GCS, GGS).

Industry

Biomedical

Sub Group

Pathogen

Application No.

20170196962

Others

Related Materials

van Sorge, N.M. et al. 2011. Streptococcus Pyogenes Group A Carbohydrate as Virulence Factor and Vaccine Candidate. Microbial Pathogenesis and Host Response Symposium, Cold Spring Harbor, New York.
Cole JN, Barnett TC, Nizet V, Walker MJ. Molecular Insight Into Invasive Group A Streptococcal Disease. Nat Rev Microbiol. 2011 Sep 16;9(10):724-36.

Tech ID/UC Case

22219/2012-011-0

Related Cases

2012-011-0

Country/Region

USA

For more information, please click Here